Photocure ASA Reports Impressive Q3 2025 Results
Photocure ASA, known as the leader in bladder cancer solutions, has recently shared its financial accomplishments for the third quarter of 2025. The company reported impressive revenues of NOK 134.1 million, showing a notable increase from NOK 120.1 million during the same period last year. Coupled with an EBITDA of NOK 10.2 million, this quarter marks a significant leap from NOK 5.0 million in Q3 2024, reflecting the company’s effective business strategies and growth initiatives.
Strategic Business Initiatives
“Photocure has showcased another successful quarter, continuing our trend of double-digit revenue growth and positive EBITDA,” stated Dan Schneider, the President and CEO of Photocure. He emphasized the company's commitment to precision diagnostics for bladder cancer while maintaining a disciplined approach to execution.
As part of its growth strategy, the company has focused on expanding blue light cystoscopy (BLC) services. In Q3 2025 alone, Photocure successfully installed 14 new Saphira towers across the United States, which includes enhancements to seven existing accounts. In response to the increasing demand, the company’s partner, ForTec, added six additional BLC towers, increasing their mobile solution capability to a total of 24. This expansion has resulted in 373 active accounts in the U.S., marking a 23% increase from the previous quarter.
Growth in Europe
Not only is Photocure making strides in the U.S., but its influence extends across Europe as well. Since the launch of the Olympus Visera Elite III BLC systems in Q1 2025, a total of 49 units have been installed, underscoring the demand for Photocure's innovative solutions in the European market.
Innovative Partnerships to Enhance Diagnosis
In a groundbreaking move post-quarter closure, Photocure announced a partnership with Intelligent Scopes Corporation (ISC), a U.S. subsidiary of Claritas HealthTech. This collaboration aims to create AI software that enhances BLC procedures, focusing on real-time support for physicians, with the goal of improving early-stage bladder cancer detection and accurate diagnoses.
“By partnering with ISC, we are positioned to pursue FDA clearance for this innovative software,” Schneider noted. “Photocure will hold exclusive rights to commercialize this solution through its sales networks and also license it to other medical device manufacturers after securing regulatory approval.”
Future Growth Prospects
The future looks bright for Photocure ASA as it anticipates sustained revenue growth driven by the adoption of rigid kits, mobile BLC expansion, and high-definition upgrades. This is further supported by recent approvals of treatments for non-muscle invasive bladder cancer (NMIBC), which encourage earlier detection and management strategies, reinforcing Photocure's pivotal place in the burgeoning healthcare landscape.
Potential catalysts for growth also include advancements in CMS reimbursement frameworks, reintroducing flexible BLC products, and new equipment manufacturer entrants to the market. Additionally, a licensing agreement with Asieris regarding Cevira anticipates triggering significant financial milestones pending regulatory approvals.
Financial Outlook and Conclusion
For this quarter, Photocure’s total revenue reached NOK 135.0 million, an increase from NOK 120.2 million, alongside an EBIT of NOK 2.9 million, compared to a loss last year. The company's cash reserves stand strong at NOK 247.8 million, positioning it favorably for continued operational investments and strategic initiatives moving forward.
As Photocure ASA accumulates momentum in its groundbreaking approaches and innovative partnerships, the company is well-positioned for ongoing success in the bladder cancer sector. They are committed to leveraging their technological advancements and partnerships to profoundly enhance outcomes for bladder cancer patients globally.
Frequently Asked Questions
What were Photocure ASA's revenues for Q3 2025?
The company reported revenues of NOK 134.1 million for the third quarter of 2025.
What growth does Photocure ASA anticipate moving forward?
Photocure expects product revenue growth between 8% to 10% on a constant currency basis.
Who is the CEO of Photocure ASA?
The current President and CEO is Dan Schneider.
What is the purpose of the partnership with Intelligent Scopes Corporation?
The partnership focuses on developing AI software to enhance early-stage detection and diagnosis of bladder cancer during BLC procedures.
How many active accounts did Photocure ASA have in the U.S. by the end of Q3 2025?
Photocure ASA had 373 active accounts in the U.S. by the end of the third quarter of 2025.
